Mdm2
Inhibitory Selectivity
Isoform-specific Inhibitors
Mdm2 Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2678 |
NSC 207895NSC 207895 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase. |
Median overall survival of mice (n = 5 mice in vehicle and PYR-41; n = 4 mice in NSC group) inoculated with IOWA-1T xenografts were increased to 43 ± 0.5 and 39 ± 2 days with PYR-41 (PYR) and NSC-207895 (NSC), respectively, compared with a vehicle-treated control group 33 ± 1 days (*p < 0.05).
|
|
| S8059 |
Nutlin-3aNutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner. |
Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment. |
|
| S7030 |
RG-7112RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor with HTRF IC50 of 18 nM. |
||
| S7875 |
NVP-CGM097NVP-CGM097 is a highly potent and selective MDM2 inhibitor with Ki value of 1.3 nM for hMDM2 in TR-FRET assay. It binds to the p53 binding-site of the Mdm2 protein, disrupting the interaction between both proteins, leading to an activation of the p53 pathway. |
(C) SACi2 effects are dependent on MT-kinetochore attachments. The graph shows percentage of cells undergoing forced mitotic exit by SACi2 or DMSO in various pretreatment conditions (mean ± SEM, three independent assays). Nocodazole (Noc) was used at 70 nM and 3 μM, vinblastine (Vbl) at 1 μM, taxol (Tx) at 600 nM and monastrol (Mon) at 100 μM concentrations and were added 8 h before addition of DMSO or SACi2. MG132 (20 μM) was added 1 h before nocodazole.
|
|
| S8403 |
MX69MX69 is a MDM2/XIAP inhibitor that binds to MDM2 RING protein with binding Kd values of 2.34 μM. It is used for cancer treatment. |
||
| S0167 |
RO8994RO8994 is a potent and selective small-molecule MDM2 inhibitor with IC50 values of 5 nM in HTRF binding assays and 20 nM in MTT proliferation assays, respectively. |
||
| S2341 |
(-)-Parthenolide(-)-Parthenolide, an inhibitor of the Nuclear Factor-κB Pathway, specifically depletes HDAC1 protein without affecting other class I/II HDACs; Also promotes the ubiquitination of MDM2 and activates p53 cellular functions. |
-Parthenolide-S234101W0220161110.gif)
-Parthenolide-S234101W0220161110.gif)
G. To evaluate effects of IKBKE/TBK1 inhibition on NF-κB signaling in Ewing, TC32 cells were incubated with CYT387 for six hours prior to stimulation with TNF-α (30 ng/mL). IκBα degradation was measured by harvesting TC32 cells thirty minutes after stimulation with TNF-α. TNF-α stimulation resulted in degradation of IκBα, and this effect was attenuated with CYT387 treatment. Parthenolide, an inhibitor of IκBα phosphorylation was used as a positive control. Similar effects of CYT387 activity were seen in HEK-293T cells which also express IKBKΕ. Nuclear extracts were prepared from TC32 cells harvested following forty-five minutes of TNF-α stimulation. Treatment with CYT387 resulted in decreased nuclear localization of NF-κB family proteins RelA/p65 and c-Rel. There was a modest impairment of p50 nuclear localization as compared to parthenolide and DMSO controls and no change in p52 nuclear localization. RelB (not shown) is not expressed in TC32 cells |
|
| S1061 |
Nutlin-3Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells. |
Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.
|
|
| S8065 |
Nutlin-3bNutlin-3b ((+)-Nutlin-3) is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a. |
Dissociative effect of Nutlin-3a, Nutlin-3b, and RO-5963 on the preformed p53·MDM2 complex. Representative electrophoresis polyacrylamide gels in nondenaturing conditions for the analysis of the dissociation power of the inhibitors tested. (A) The reaction mixture containing 25 M p53·MDM2 complex, treated in the absence (lane 3) or in the presence (lanes 4-14) of 0.040, 0.060, 0.080, 0.12,
0.33, 0.67, 1.33, 3.33, 6.67, 33.33, and 333.33 μM Nutlin-3a, respectively, were run on a 12% nondenaturing polyacrylamide gel. Thirty micromolar MDM2 and p53 was run alone in lanes 1 and 2, respectively. (B) As in (A), but using Nutlin-3b, at concentration of (lanes 4-14) of 1.33, 6.67, 13.33, 20.00, 66.67, 133.33, 266.67, 333.33, 400.00, 833.33, and 1666.67 μM. p53 and MDM2 (25 μM both) were run alone in lanes 1 and 2, respectively. (C) As in (A), but using RO-5963, at concentration of 0.10, 0.21, 0.42, 0.83, 1.67, 3.33, 8.33, 16.67, 33.33, 166.67, and 333.33 μM (lanes 4-14), respectively. (D) The percentage of the residual p53·MDM2 complex was reported in a semilogarithmic plot, at the corresponding concentration of Nutlin-3a (empty circles), RO-5963 (triangles), and Nutlin-3b (filled circles), respectively. (E) The percentage of MDM2 dissociated from the complex was reported as a function of the inhibitor concentration. Curve fitting was done using the hyperbolic function. Symbols as in (D).
|
|
| S7649 |
MI-773 (SAR405838)MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1. |
A panel of four NB cell lines were seeded in six-well plates with indicated concentrations of SAR405838 and agar, and grown for 2 to 3 weeks. Cells were stained with crystal violet for 4 hours. Colonies were counted and colony numbers were represented as % vehicle ± S.D. with P < 0.05 (*), P < 0.01 (**) or P < 0.001 (***) (Student's t-test, two-tailed) as indicated.
|
|
| S7489 |
YH239-EEYH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2678 |
NSC 207895NSC 207895 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase. |
Median overall survival of mice (n = 5 mice in vehicle and PYR-41; n = 4 mice in NSC group) inoculated with IOWA-1T xenografts were increased to 43 ± 0.5 and 39 ± 2 days with PYR-41 (PYR) and NSC-207895 (NSC), respectively, compared with a vehicle-treated control group 33 ± 1 days (*p < 0.05).
|
|
| S8059 |
Nutlin-3aNutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner. |
Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment. |
|
| S7030 |
RG-7112RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor with HTRF IC50 of 18 nM. |
||
| S7875 |
NVP-CGM097NVP-CGM097 is a highly potent and selective MDM2 inhibitor with Ki value of 1.3 nM for hMDM2 in TR-FRET assay. It binds to the p53 binding-site of the Mdm2 protein, disrupting the interaction between both proteins, leading to an activation of the p53 pathway. |
(C) SACi2 effects are dependent on MT-kinetochore attachments. The graph shows percentage of cells undergoing forced mitotic exit by SACi2 or DMSO in various pretreatment conditions (mean ± SEM, three independent assays). Nocodazole (Noc) was used at 70 nM and 3 μM, vinblastine (Vbl) at 1 μM, taxol (Tx) at 600 nM and monastrol (Mon) at 100 μM concentrations and were added 8 h before addition of DMSO or SACi2. MG132 (20 μM) was added 1 h before nocodazole.
|
|
| S8403 |
MX69MX69 is a MDM2/XIAP inhibitor that binds to MDM2 RING protein with binding Kd values of 2.34 μM. It is used for cancer treatment. |
||
| S0167 |
RO8994RO8994 is a potent and selective small-molecule MDM2 inhibitor with IC50 values of 5 nM in HTRF binding assays and 20 nM in MTT proliferation assays, respectively. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2341 |
(-)-Parthenolide(-)-Parthenolide, an inhibitor of the Nuclear Factor-κB Pathway, specifically depletes HDAC1 protein without affecting other class I/II HDACs; Also promotes the ubiquitination of MDM2 and activates p53 cellular functions. |
-Parthenolide-S234101W0220161110.gif)
G. To evaluate effects of IKBKE/TBK1 inhibition on NF-κB signaling in Ewing, TC32 cells were incubated with CYT387 for six hours prior to stimulation with TNF-α (30 ng/mL). IκBα degradation was measured by harvesting TC32 cells thirty minutes after stimulation with TNF-α. TNF-α stimulation resulted in degradation of IκBα, and this effect was attenuated with CYT387 treatment. Parthenolide, an inhibitor of IκBα phosphorylation was used as a positive control. Similar effects of CYT387 activity were seen in HEK-293T cells which also express IKBKΕ. Nuclear extracts were prepared from TC32 cells harvested following forty-five minutes of TNF-α stimulation. Treatment with CYT387 resulted in decreased nuclear localization of NF-κB family proteins RelA/p65 and c-Rel. There was a modest impairment of p50 nuclear localization as compared to parthenolide and DMSO controls and no change in p52 nuclear localization. RelB (not shown) is not expressed in TC32 cells |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S1061 |
Nutlin-3Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells. |
Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.
|
|
| S8065 |
Nutlin-3bNutlin-3b ((+)-Nutlin-3) is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a. |
Dissociative effect of Nutlin-3a, Nutlin-3b, and RO-5963 on the preformed p53·MDM2 complex. Representative electrophoresis polyacrylamide gels in nondenaturing conditions for the analysis of the dissociation power of the inhibitors tested. (A) The reaction mixture containing 25 M p53·MDM2 complex, treated in the absence (lane 3) or in the presence (lanes 4-14) of 0.040, 0.060, 0.080, 0.12,
0.33, 0.67, 1.33, 3.33, 6.67, 33.33, and 333.33 μM Nutlin-3a, respectively, were run on a 12% nondenaturing polyacrylamide gel. Thirty micromolar MDM2 and p53 was run alone in lanes 1 and 2, respectively. (B) As in (A), but using Nutlin-3b, at concentration of (lanes 4-14) of 1.33, 6.67, 13.33, 20.00, 66.67, 133.33, 266.67, 333.33, 400.00, 833.33, and 1666.67 μM. p53 and MDM2 (25 μM both) were run alone in lanes 1 and 2, respectively. (C) As in (A), but using RO-5963, at concentration of 0.10, 0.21, 0.42, 0.83, 1.67, 3.33, 8.33, 16.67, 33.33, 166.67, and 333.33 μM (lanes 4-14), respectively. (D) The percentage of the residual p53·MDM2 complex was reported in a semilogarithmic plot, at the corresponding concentration of Nutlin-3a (empty circles), RO-5963 (triangles), and Nutlin-3b (filled circles), respectively. (E) The percentage of MDM2 dissociated from the complex was reported as a function of the inhibitor concentration. Curve fitting was done using the hyperbolic function. Symbols as in (D).
|
|
| S7649 |
MI-773 (SAR405838)MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1. |
A panel of four NB cell lines were seeded in six-well plates with indicated concentrations of SAR405838 and agar, and grown for 2 to 3 weeks. Cells were stained with crystal violet for 4 hours. Colonies were counted and colony numbers were represented as % vehicle ± S.D. with P < 0.05 (*), P < 0.01 (**) or P < 0.001 (***) (Student's t-test, two-tailed) as indicated.
|
|
| S7489 |
YH239-EEYH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer. |
